This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1971 Apr;55(2):205-8.

Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520)

F J Ansfield, G Ramirez

PMID: 4256145

Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520)

F J Ansfield et al. Cancer Chemother Rep. 1971 Apr.

. 1971 Apr;55(2):205-8.

Authors

F J Ansfield, G Ramirez

PMID: 4256145

No abstract available

PubMed Disclaimer

Similar articles

Clinical evaluation of 5-bromo-5-fluoro-6-methoxy-dihydro-2'-deoxyuridine.
Van Dyk JJ, Clarkson BD, Duschinsky R, Keller O, La Sala E, Krakoff IH. Van Dyk JJ, et al. Cancer Res. 1967 Nov;27(11):2129-36. Cancer Res. 1967. PMID: 4294532 No abstract available.
Thymidine and 5-FU: a Phase II pilot study in colorectal and breast carcinomas.
Presant CA, Multhauf P, Klein L, Chan C, Chang FF, Hum G, Joseph R, Opfell R, Lemkin S, Shiftan T, Plotkin D. Presant CA, et al. Cancer Treat Rep. 1983 Jul-Aug;67(7-8):735-6. Cancer Treat Rep. 1983. PMID: 6871891 No abstract available.
[Phase II study of 5'-DFUR in gastrointestinal and breast cancer].
Tominaga T, Kitamura M, Hayashi K, Takahashi I, Kosaki G. Tominaga T, et al. Gan To Kagaku Ryoho. 1985 Nov;12(11):2172-8. Gan To Kagaku Ryoho. 1985. PMID: 2933000 Japanese.
[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR].
Taguchi T. Taguchi T. Gan To Kagaku Ryoho. 1996 Jul;23(8):1019-29. Gan To Kagaku Ryoho. 1996. PMID: 8687216 Review. Japanese.
Chemotherapy of residual disease in solid tumours.
Kenis Y. Kenis Y. Rev Eur Etud Clin Biol. 1971 Feb;16(2):103-7. Rev Eur Etud Clin Biol. 1971. PMID: 4324078 Review. No abstract available.

See all similar articles

Cited by

Experimental herpes simplex virus type 1 encephalitis: treatment with 5-trifluoromethyl-2'-deoxyuridine.
Clough DW, Parkhurst JR. Clough DW, et al. Antimicrob Agents Chemother. 1977 Feb;11(2):307-11. doi: 10.1128/AAC.11.2.307. Antimicrob Agents Chemother. 1977. PMID: 192143 Free PMC article.
Antitumor activity of FTC-092, a masked 5-trifluoromethyl-2'-deoxyuridine derivative.
Takeda S, Yamashita J, Saito H, Uchida J, Satake H, Yamada Y, Unemi N, Wataya Y, Hayatsu H. Takeda S, et al. Cancer Chemother Pharmacol. 1991;29(2):122-6. doi: 10.1007/BF00687321. Cancer Chemother Pharmacol. 1991. PMID: 1760854
The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH, Prins HJ, van Gelderop E, Peters GJ. Temmink OH, et al. Br J Cancer. 2007 Jan 15;96(1):61-6. doi: 10.1038/sj.bjc.6603507. Epub 2006 Dec 19. Br J Cancer. 2007. PMID: 17179993 Free PMC article.
Antitumor cell and antimetabolic effects of 5-ethyl-2'-deoxyuridine and 5'-substituted 5-ethyl-2'-deoxyuridine derivatives.
Balzarini J, De Clercq E, Kiefer G, Keppeler K, Buchele A. Balzarini J, et al. Invest New Drugs. 1984;2(1):35-47. doi: 10.1007/BF00173785. Invest New Drugs. 1984. PMID: 6469497
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F, Nagase H, Yokogawa T, Oguchi K, Ishida K, Osada A, Kazuno H, Yamada Y, Matsuo K. Tanaka N, et al. Oncol Rep. 2014 Dec;32(6):2319-26. doi: 10.3892/or.2014.3487. Epub 2014 Sep 17. Oncol Rep. 2014. PMID: 25230742 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database